Anticancer Activity of Measles-Mumps-Rubella MMR Vaccine Viruses against Glioblastoma.
MMR vaccine
glioblastoma
oncolytic viruses
virotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Aug 2023
28 Aug 2023
Historique:
received:
28
07
2023
revised:
25
08
2023
accepted:
26
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Oncolytic viruses (OVs) have been utilized since 1990s for targeted cancer treatment. Our study examined the Measles-Mumps-Rubella (MMR) vaccine's cancer-killing potency against Glioblastoma (GBM), a therapy-resistant, aggressive cancer type. We used GBM cell lines, primary GBM cells, and normal mice microglial cells, to assess the MMR vaccine's efficacy through cell viability, cell cycle analysis, intracellular viral load via RT-PCR, and Transmission Electron Microscopy (TEM). After 72 h of MMR treatment, GBM cell lines and primary GBM cells exhibited significant viability reduction compared to untreated cells. Conversely, normal microglial cells showed only minor changes in viability and morphology. Intracellular viral load tests indicated GBM cells' increased sensitivity to MMR viruses compared to normal cells. The cell cycle study also revealed measles and mumps viruses' crucial role in cytopathic effects, with the rubella virus causing cell cycle arrest. Herein the reported results demonstrate the anti-cancer activity of the MMR vaccine against GBM cells. Accordingly, the MMR vaccine warrants further study as a potential new tool for GBM therapy and relapse prevention. Therapeutic potential of the MMR vaccine has been found to be promising in earlier studies as well.
Sections du résumé
BACKGROUND
BACKGROUND
Oncolytic viruses (OVs) have been utilized since 1990s for targeted cancer treatment. Our study examined the Measles-Mumps-Rubella (MMR) vaccine's cancer-killing potency against Glioblastoma (GBM), a therapy-resistant, aggressive cancer type.
METHODOLOGY
METHODS
We used GBM cell lines, primary GBM cells, and normal mice microglial cells, to assess the MMR vaccine's efficacy through cell viability, cell cycle analysis, intracellular viral load via RT-PCR, and Transmission Electron Microscopy (TEM).
RESULTS
RESULTS
After 72 h of MMR treatment, GBM cell lines and primary GBM cells exhibited significant viability reduction compared to untreated cells. Conversely, normal microglial cells showed only minor changes in viability and morphology. Intracellular viral load tests indicated GBM cells' increased sensitivity to MMR viruses compared to normal cells. The cell cycle study also revealed measles and mumps viruses' crucial role in cytopathic effects, with the rubella virus causing cell cycle arrest.
CONCLUSION
CONCLUSIONS
Herein the reported results demonstrate the anti-cancer activity of the MMR vaccine against GBM cells. Accordingly, the MMR vaccine warrants further study as a potential new tool for GBM therapy and relapse prevention. Therapeutic potential of the MMR vaccine has been found to be promising in earlier studies as well.
Identifiants
pubmed: 37686579
pii: cancers15174304
doi: 10.3390/cancers15174304
pmc: PMC10486717
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG2017-20699
Références
J Clin Oncol. 2002 May 1;20(9):2251-66
pubmed: 11980996
Neurosurg Focus. 2021 Feb;50(2):E7
pubmed: 33524944
Clin Cancer Res. 2015 Mar 15;21(6):1305-12
pubmed: 25424857
Gynecol Oncol. 2017 Sep;146(3):477-483
pubmed: 28756871
Am J Pathol. 2012 Jun;180(6):2188-200
pubmed: 22542493
Mol Ther. 2012 Oct;20(10):1998-2003
pubmed: 22871663
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Mol Ther. 2004 Nov;10(5):958-66
pubmed: 15509513
Clin Cancer Res. 2010 Jun 1;16(11):3035-43
pubmed: 20501623
Clin Cancer Res. 2013 May 15;19(10):2734-44
pubmed: 23493351
Brain Pathol. 2014 Jul;24(4):360-70
pubmed: 24521322
Viruses. 2021 Aug 24;13(9):
pubmed: 34578259
Clin Cancer Res. 2008 Nov 1;14(21):7127-37
pubmed: 18981012
Clin Cancer Res. 2011 Feb 15;17(4):888-95
pubmed: 21304001
Hum Gene Ther. 1999 Nov 20;10(17):2869-78
pubmed: 10584932
Mol Ther Nucleic Acids. 2021 Jun 24;25:406-415
pubmed: 34484865
Mol Cancer Ther. 2017 May;16(5):787-792
pubmed: 28468864
J Exp Clin Cancer Res. 2022 Feb 8;41(1):53
pubmed: 35135603
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76
pubmed: 24837889
Nat Med. 2000 Aug;6(8):879-85
pubmed: 10932224
Cancer Biol Ther. 2009 Apr;8(8):676-82
pubmed: 19242097
Invest New Drugs. 2013 Jun;31(3):696-706
pubmed: 22886613
Oncotarget. 2015 Feb 28;6(6):4467-81
pubmed: 25714011
J Urol. 2012 Dec;188(6):2391-7
pubmed: 23088985
Cancer Res. 2001 Oct 15;61(20):7464-72
pubmed: 11606381
Expert Opin Biol Ther. 2008 Feb;8(2):213-20
pubmed: 18194077
Cell Rep. 2022 Jun 14;39(11):110935
pubmed: 35705036
Chin Neurosurg J. 2022 Jan 19;8(1):2
pubmed: 35045874
J Gen Virol. 1999 Jul;80 ( Pt 7):1657-1664
pubmed: 10423133
Onco Targets Ther. 2018 Oct 10;11:6447-6458
pubmed: 30349292
Cancer Res. 2010 Feb 1;70(3):875-82
pubmed: 20103634
Mol Ther. 2008 Mar;16(3):627-32
pubmed: 18253152
Cancers (Basel). 2021 Feb 04;13(4):
pubmed: 33557101
Neuro Oncol. 2016 Aug;18(8):1137-45
pubmed: 26843484
Clin Cancer Res. 2011 Feb 1;17(3):581-8
pubmed: 21106728
Mol Cancer Ther. 2006 May;5(5):1087-98
pubmed: 16731740
Nat Med. 2023 Jun;29(6):1370-1378
pubmed: 37188783
Cancer Gene Ther. 2013 Nov;20(11):642-9
pubmed: 24052127
Clin Cancer Res. 2019 Oct 1;25(19):5818-5831
pubmed: 31273010
Cancer Gene Ther. 2012 Nov;19(11):788-95
pubmed: 22996742
Biochem Biophys Rep. 2018 Jan 02;13:58-62
pubmed: 29326986
Hum Gene Ther. 1999 Nov 20;10(17):2741-55
pubmed: 10584921
Mol Ther. 2007 May;15(5):1016-23
pubmed: 17375076
Mol Ther. 2014 May;22(5):1056-62
pubmed: 24553100
Cancer Res. 2002 Sep 1;62(17):4968-76
pubmed: 12208748
Genes Dis. 2021 Dec 16;10(2):430-446
pubmed: 37223527
Emerg Infect Dis. 2022 Apr;28(4):906-908
pubmed: 35318930
Int J Mol Sci. 2022 Feb 04;23(3):
pubmed: 35163730
Mol Ther. 2011 Sep;19(9):1737-46
pubmed: 21673660
Mol Cancer. 2010 Jul 20;9:194
pubmed: 20646316
Cell Res. 2012 Jan;22(1):90-106
pubmed: 21876555
Mol Ther. 2007 Apr;15(4):651-9
pubmed: 17299401
Int J Cancer. 2012 Apr 15;130(8):1937-47
pubmed: 21630267
Materials (Basel). 2021 Dec 16;14(24):
pubmed: 34947381
Neurosurg Focus. 2021 Feb;50(2):E10
pubmed: 33524942
Expert Opin Ther Targets. 2015 Jul;19(7):941-55
pubmed: 25835638
Clin Cancer Res. 2007 Feb 1;13(3):977-85
pubmed: 17289893
BMC Cancer. 2020 Jul 6;20(1):626
pubmed: 32631390
Gynecol Oncol. 2013 Sep;130(3):518-24
pubmed: 23756180
Vaccine X. 2023 Feb 04;13:100268
pubmed: 36814595
Blood. 2005 Oct 1;106(7):2287-94
pubmed: 15961518
Mol Ther. 2006 Jul;14(1):107-17
pubmed: 16690359
J Dtsch Dermatol Ges. 2003 Feb;1(2):120-5
pubmed: 16285179
Pediatr Blood Cancer. 2015 May;62(5):743-50
pubmed: 25307519
DNA Cell Biol. 2023 Jun;42(6):267-273
pubmed: 36350682
Sci Rep. 2018 Jan 23;8(1):1420
pubmed: 29362367
Cancer Gene Ther. 2007 Nov;14(11):885-93
pubmed: 17704755
Front Endocrinol (Lausanne). 2012 Apr 25;3:59
pubmed: 22645523
Future Oncol. 2020 Oct;16(28):2251-2264
pubmed: 32744059
Anticancer Res. 2019 Nov;39(11):6073-6086
pubmed: 31704835
Oncotarget. 2015 Aug 21;6(24):19976-89
pubmed: 26280277
IUBMB Life. 2010 Feb;62(2):92-102
pubmed: 19960541
Mol Ther. 2010 Feb;18(2):429-34
pubmed: 19935775
Clin Cancer Res. 2010 Nov 1;16(21):5277-87
pubmed: 20978148
BMC Cancer. 2018 Mar 27;18(1):321
pubmed: 29580202
Mol Ther Methods Clin Dev. 2022 Sep 24;27:90-92
pubmed: 36212907
Int J Mol Sci. 2023 Jan 28;24(3):
pubmed: 36768863
Clin Cancer Res. 2000 Mar;6(3):798-806
pubmed: 10741699
Clin Cancer Res. 2014 Dec 1;20(23):5946-55
pubmed: 25294913
Curr Cancer Drug Targets. 2018;18(2):177-187
pubmed: 28228086
Am J Pathol. 2013 Oct;183(4):1281-1292
pubmed: 23906809
Pediatr Blood Cancer. 2015 May;62(5):751-8
pubmed: 25728527
Cancer Sci. 2016 Oct;107(10):1373-1379
pubmed: 27486853
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
Leukemia. 2017 Dec;31(12):2791-2798
pubmed: 28439108
Elife. 2018 Jun 04;7:
pubmed: 29863470
Viruses. 2023 Feb 16;15(2):
pubmed: 36851761
Front Mol Biosci. 2022 Mar 03;9:773662
pubmed: 35309512